We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
September 20, 2023
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September 26, 2023
September 12, 2023
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)